The shift from intravenous infusions to subcutaneous injections is often framed as a victory for patient comfort. In the high-stakes world of oncology, where treatment days can be grueling and time-consuming, the promise of a quicker administration is an easy sell. Although, a new critique published in the Journal of Clinical Oncology suggests that this convenience may come with a hidden, systemic price tag.
Bishal Gyawali, an associate professor at Queen’s University, is questioning the actual value of subcutaneous pembrolizumab, a formulation of the widely used immunotherapy drug. While the pharmaceutical industry emphasizes the time saved in the clinic, Gyawali and his colleagues argue that the transition may be less about patient benefit and more about a strategic corporate maneuver known as “patent hopping.”
Pembrolizumab, marketed as Keytruda, is a PD-1 inhibitor used to treat a vast array of cancers by helping the immune system recognize and attack tumor cells. For years, it has been administered via intravenous (IV) infusion, a process that requires patients to sit in a clinic for several hours. The subcutaneous version—a shot administered under the skin—drastically reduces this time. But in his recent analysis, Gyawali asks whether this marginal gain in convenience justifies the potential costs to health systems and the long-term accessibility of the drug.
The High Cost of Convenience
The core of the debate centers on whether the subcutaneous formulation offers any clinical advantage over the IV version, or if it simply serves as a tool to extend market exclusivity. In the pharmaceutical industry, “patent hopping” occurs when a company introduces a slightly modified version of a drug—such as a new delivery method—just as the original patent is nearing expiration. By shifting the market toward the new version, companies can potentially delay the entry of cheaper biosimilars, which are highly similar, lower-cost versions of biologic drugs.
Gyawali suggests that this strategy is expensive for health systems and may ultimately thwart efforts toward dose optimization. Dose optimization is the process of determining the minimum effective dose of a drug to maintain efficacy while reducing toxicity and cost. By introducing a new formulation, the focus shifts away from refining the dosage of the existing, soon-to-be-generic version and toward a new, protected product.
This concern is not an isolated one. Gyawali’s current perform builds on his previous research regarding the “cost of convenience” in cancer care, arguing that when “convenience” is used as the primary justification for new, expensive formulations, the broader health system often bears the financial burden without a corresponding increase in patient survival or quality of life.
Impact on Health Systems and Biosimilar Access
The implications of this shift extend beyond the individual patient’s clinic visit. Health systems, particularly those in public-funded models, operate on finite budgets. When a new formulation is introduced at a premium price, it can drain resources that might otherwise be used to expand access to other life-saving treatments.
the arrival of biosimilars is often the only way to significantly lower the cost of immunotherapies. According to the U.S. Food and Drug Administration (FDA), biosimilars can introduce competition that drives down prices for the entire class of biologics. If a significant portion of the patient population is migrated to a new subcutaneous formulation before the IV biosimilars can take hold, the expected price drop may be muted, keeping costs high for years longer than necessary.
Comparing Administration Methods
| Feature | Intravenous (IV) | Subcutaneous (subQ) |
|---|---|---|
| Administration Time | Hours (Infusion) | Minutes (Injection) |
| Patient Experience | Higher clinic dwell time | Reduced clinic dwell time |
| Market Status | Approaching biosimilar entry | Newer, patent-protected |
| Systemic Cost | Lower drug cost (eventually) | Potential for sustained high cost |
The Tension Between Patient Comfort and Public Health
From a clinical perspective, the appeal of subcutaneous administration is undeniable. For a patient traveling long distances to a cancer center, saving three hours per visit is a significant quality-of-life improvement. However, Gyawali’s critique asks a fundamental public health question: at what point does the cost of that convenience become unsustainable?
When the pharmaceutical industry prioritizes formulation changes over dose optimization, the medical community loses the opportunity to understand if less of the drug could achieve the same result. If a lower dose of the IV version were found to be equally effective, it would not only reduce the cost per patient but potentially reduce the side effects associated with immunotherapy.
The dialogue surrounding the value of subcutaneous pembrolizumab highlights a growing friction in modern medicine: the balance between the individual patient’s immediate experience and the collective ability of a health system to provide affordable care to all.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their oncology team regarding the most appropriate administration method for their specific treatment plan.
As regulatory bodies and health systems continue to evaluate the integration of new drug formulations, the focus will likely shift toward demanding more transparent data on the actual value added by these changes. The next critical checkpoint will be the emergence of the first wave of pembrolizumab biosimilars and whether health systems successfully transition patients to these lower-cost alternatives despite the availability of subcutaneous options.
We invite readers to share their thoughts on the balance between treatment convenience and drug affordability in the comments below.
